$AJJ Medtech(584.SI)$   AJJ Medtech announced a new institutional medical supply contract worth approximately S$3 million, covering biodegradable medical consumables. The contract starts on 1 June 2026, with an initial 2-year term and an extension option, while the company’s cumulative institutional revenue pipeline now exceeds S$8 million. [AI-readable] Company: AJJ Medtech Holdings Limited Ticker: SGX: 584 Announcement Date: 9 March 2026 Announcement Title: AJJ Medtech Secures S$3M Institutional Contract for Biodegradable Medical Consumables Contracting Entity: AJJ Healthcare Management Pte. Ltd. (wholly owned subsidiary) Customer Type: A network of Singapore healthcare institutions Contract Value: Approximately S$3 million Product

$新电信(Z74.SI)$   Singtel is up +51% in the past year, but this rally is mostly driven by re-rating. The holdco discount has narrowed to ~7%, near historical lows. The issue is: core growth remains modest, and ~50% of valuation comes from Bharti.

$AJJ Medtech(584.SI)$   According to Morningstar’s quantitative equity report dated March 27, 2026, AJJ Medtech Holdings Ltd (SGX: 584) received a 4-star quantitative rating. The report shows a Price/Fair Value ratio of 0.68, implying that the stock is trading at about a 32% discount to Morningstar’s quantitative fair value estimate. Key points from the report include: Company: AJJ Medtech Holdings Ltd Ticker: SGX: 584 Morningstar quantitative rating: 4 stars Price/Fair Value: 0.68 Implied discount to fair value: about 32% 3-year revenue growth: 75% FY2025 revenue: about SGD 3.19 million FY2025 net income: about -SGD 2.93 million Economic moat: None Uncertainty: Very High Sector: Healthcare Industry: Medical D

$名创优品(MNSO)$   $名创优品(09896)$   This quarter is really about mix improvement. China same-store sales improved, overseas kept expanding, and TOPTOY stayed high-growth. MINISO now looks more like a global IP consumer platform. @名创优品 

$AJJ Medtech(584.SI)$   One chart on AJJ Medtech (SGX: 584). Morningstar’s quantitative model currently shows 4-Star, ~32% undervaluation, 75% 3Y revenue growth, and a Small Growth classification. For a micro-cap name, the key point is that AJJ is starting to show up on the market’s small-growth medtech radar. @Tiger_SG @新加坡交易所集团 @Daily_Discussion 

$阿里巴巴-W(09988)$   $阿里巴巴(BABA)$   E-commerce is still soft, but cloud is clearly accelerating. Cloud +36%, profits -57%.

$扬子江船业(BS6.SI)$   Shipbuilding is quietly entering another cycle. Yangzijiang now has an order backlog of US$22.4bn, with shipyards fully booked until 2029. The order mix is also changing. About 80% of the orderbook now comes from clean-energy vessels such as LNG and dual-fuel ships. The investment story is quite simple: visibility of earnings + 5–6% dividend yield. Among SGX industrial companies, few have this level of order visibility.

$蔚来(NIO)$  $蔚来-SW(09866)$  $蔚来(NIO.SI)$   the profit was mainly driven by lower expenses, not a structural improvement in demand.

$携程网(TCOM)$   Trip.com’s latest numbers don’t show a slowdown. Revenue grew over 20%, with double-digit growth across hotels and tickets. International revenue is still up more than 60%.

$赛富时(CRM)$   The quarter was largely inline. Growth is still around 10%, and SaaS multiples remain compressed. The interesting part is AgentForce. ARR is up nearly 170%, with expansion mostly from existing customers.

$贝壳(BEKE)$   If you want a read on housing activity, watch Ke Holdings. Transactions look more stable, but not rebounding.

$亚马逊(AMZN)$   This quarter wasn’t about retail. AWS growth re-accelerated above 23%, with backlog rising alongside it. Retail supports margins, but AWS is driving growth again.

$谷歌(GOOG)$   This quarter wasn’t about the beat. AI is turning single searches into longer, decision-driven conversations. That’s what’s changing: the value of each search.

$Meta Platforms, Inc.(META)$   This quarter wasn’t about macro tailwinds. Ad volume and pricing both improved, but the real change is AI lifting engagement, conversion, and ad products at the same time. This isn’t an ad rebound. It’s an ad engine upgrade.

$微软(MSFT)$   This wasn’t a “one-quarter surprise” story. Azure and Copilot demand stayed strong, supply is the real constraint. The target price was trimmed for one reason: AI capex is higher than expected. But the conclusion didn’t change — more spending doesn’t mean weaker business, it means AI is moving deeper into the core.

$LMS Compliance(LMS.SI)$   The base case is simple: compliance demand is mandatory, not cyclical. What stands out in this initiation note: Testing is the base: high repeat business (85%+), lab testing dominates revenue (FY24: 93.6%) ESG is the growth layer: Singapore’s mandatory climate disclosures (from FY2025) and Malaysia’s phased rollout expand third-party assurance demand Financials are clean: FY24 net margin 20.5%, EBITDA ma